{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:05:33Z","timestamp":1792105533309,"version":"4.4.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40257-026-01037-y","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:39:20Z","timestamp":1778611160000},"page":"765-777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transforming Outcomes in Advanced Basal Cell Carcinoma: The Evolving Role of Systemic Therapy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6994-809X","authenticated-orcid":false,"given":"Anna A. L.","family":"Massella Patsea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babette J. A.","family":"Verkouteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"7","key":"1037_CR1","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/jid.2010.58","volume":"130","author":"C Holterhues","year":"2010","unstructured":"Holterhues C, Vries E, Louwman MW, Koljenovic S, Nijsten T. Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. J Invest Dermatol. 2010;130(7):1807\u201312.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"1037_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamadermatol.2025.1276","volume":"161","author":"R Wang","year":"2025","unstructured":"Wang R, Chen Y, Shao X, Chen T, Zhong J, Ou Y, et al. Burden of skin cancer in older adults from 1990 to 2021 and modelled projection to 2050. JAMA Dermatol. 2025;161(7):715\u201322.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1037_CR3","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/bjd.20871","volume":"186","author":"K Schreuder","year":"2022","unstructured":"Schreuder K, Hollestein L, Nijsten TEC, Wakkee M, Louwman MWJ. A nationwide study of the incidence and trends of first and multiple basal cell carcinomas in the Netherlands and prediction of future incidence. Br J Dermatol. 2022;186(3):476\u201384.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1037_CR4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/bjd.13217","volume":"171","author":"J Dreier","year":"2014","unstructured":"Dreier J, Cheng PF, Bogdan Alleman I, Gugger A, Hafner J, Tschopp A, et al. Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol. 2014;171(5):1066\u201372.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1037_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2016.06.020","volume":"75","author":"G Goldenberg","year":"2016","unstructured":"Goldenberg G, Karagiannis T, Palmer JB, Lotya J, O\u2019Neill C, Kisa R, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: a retrospective cohort study. J Am Acad Dermatol. 2016;75(5):957\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1037_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2023.0056","volume":"21","author":"CD Schmults","year":"2023","unstructured":"Schmults CD, Blitzblau R, Aasi SZ, Alam M, Amini A, Bibee K, et al. Basal cell skin cancer, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(11):1181\u2013203.","journal-title":"J Natl Compr Canc Netw"},{"key":"1037_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113254","volume":"192","author":"K Peris","year":"2023","unstructured":"Peris K, Fargnoli MC, Kaufmann R, Arenberger P, Bastholt L, Seguin NB, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023;192:113254.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1037_CR8","doi-asserted-by":"publisher","first-page":"13206","DOI":"10.1038\/s41598-021-92592-3","volume":"11","author":"L Di Nardo","year":"2021","unstructured":"Di Nardo L, Pellegrini C, Di Stefani A, Ricci F, Fossati B, Del Regno L, et al. Molecular alterations in basal cell carcinoma subtypes. Sci Rep. 2021;11(1):13206.","journal-title":"Sci Rep"},{"issue":"3","key":"1037_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1404217","volume":"7","author":"AM Goodman","year":"2018","unstructured":"Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, et al. Genomic landscape of advanced basal cell carcinoma: implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018;7(3):e1404217.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1037_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12964-018-0220-7","volume":"16","author":"GB Carballo","year":"2018","unstructured":"Carballo GB, Honorato JR, de Lopes GPF, Spohr T. A highlight on Sonic hedgehog pathway. Cell Commun Signal. 2018;16(1):11.","journal-title":"Cell Commun Signal"},{"issue":"4","key":"1037_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/exd.12905","volume":"25","author":"T Brinkhuizen","year":"2016","unstructured":"Brinkhuizen T, van Geel M, Denil SL, De Meyer T, Kelleners-Smeets NW, Lohuis PJ, et al. Locally advanced basal cell carcinoma has a distinct methylation and transcriptomic profile. Exp Dermatol. 2016;25(4):316\u20138.","journal-title":"Exp Dermatol"},{"issue":"6S","key":"1037_CR12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaad.2022.03.023","volume":"86","author":"AC Krakowski","year":"2022","unstructured":"Krakowski AC, Hafeez F, Westheim A, Pan EY, Wilson M. Advanced basal cell carcinoma: what dermatologists need to know about diagnosis. J Am Acad Dermatol. 2022;86(6S):S1\u201313.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1037_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjd.15321","volume":"177","author":"JAC Verkouteren","year":"2017","unstructured":"Verkouteren JAC, Ramdas KHR, Wakkee M, Nijsten T. Epidemiology of basal cell carcinoma: scholarly review. Br J Dermatol. 2017;177(2):359\u201372.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1037_CR14","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/bjc.2014.270","volume":"111","author":"JT Lear","year":"2014","unstructured":"Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476\u201381.","journal-title":"Br J Cancer"},{"issue":"8","key":"1037_CR15","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1080\/13548506.2021.1952281","volume":"27","author":"A Legrand","year":"2022","unstructured":"Legrand A, Quintard B, Garrouteigt C, Beylot-Barry M, Broc G. From neglect to earlier diagnosis: a qualitative meta-synthesis of psycho-social factors associated with consultation delay in advanced basal cell carcinoma. Psychol Health Med. 2022;27(8):1793\u2013804.","journal-title":"Psychol Health Med"},{"issue":"5","key":"1037_CR16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/1097-0142(19930901)72:5<1624::AID-CNCR2820720522>3.0.CO;2-D","volume":"72","author":"HW Randle","year":"1993","unstructured":"Randle HW, Roenigk RK, Brodland DG. Giant basal cell carcinoma (T3). Who is at risk? Cancer. 1993;72(5):1624\u201330.","journal-title":"Cancer"},{"key":"1037_CR17","doi-asserted-by":"publisher","first-page":"adv43240","DOI":"10.2340\/actadv.v105.43240","volume":"105","author":"A Zwanenburg","year":"2025","unstructured":"Zwanenburg A, Van Houdt WJ, Schrijver AM, Schreuder WH, Wouters M, Plasmeijer EI. Clinical features and outcomes of locally advanced and metastatic basal cell carcinoma. Acta Derm Venereol. 2025;105:adv43240.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"1037_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-16-2051","volume":"23","author":"D Casey","year":"2017","unstructured":"Casey D, Demko S, Shord S, Zhao H, Chen H, He K, et al. FDA approval summary: sonidegib for locally advanced basal cell carcinoma. Clin Cancer Res. 2017;23(10):2377\u201381.","journal-title":"Clin Cancer Res"},{"issue":"23","key":"1037_CR19","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","volume":"366","author":"A Sekulic","year":"2012","unstructured":"Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"1037_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.annonc.2023.10.123","volume":"35","author":"KD Lewis","year":"2024","unstructured":"Lewis KD, Peris K, Sekulic A, Stratigos AJ, Dunn L, Eroglu Z, et al. Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors. Ann Oncol. 2024;35(2):221\u20138.","journal-title":"Ann Oncol"},{"issue":"2","key":"1037_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaad.2023.08.111","volume":"90","author":"AJ Stratigos","year":"2024","unstructured":"Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Lewis KD, et al. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: extended follow-up. J Am Acad Dermatol. 2024;90(2):414\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1037_CR22","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41416-020-01220-w","volume":"124","author":"BJA Verkouteren","year":"2021","unstructured":"Verkouteren BJA, Wakkee M, Reyners AKL, Nelemans P, Aarts MJB, Racz E, et al. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study. Br J Cancer. 2021;124(7):1199\u2013206.","journal-title":"Br J Cancer"},{"issue":"7","key":"1037_CR23","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1001\/jamadermatol.2016.0780","volume":"152","author":"AA Jacobsen","year":"2016","unstructured":"Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma: a systematic review and pooled analysis of interventional studies. JAMA Dermatol. 2016;152(7):816\u201324.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1037_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14656566.2022.2032646","volume":"23","author":"E Ramelyte","year":"2022","unstructured":"Ramelyte E, Restivo G, Mannino M, Levesque MP, Dummer R. Advances in the drug management of basal cell carcinoma. Expert Opin Pharmacother. 2022;23(5):573\u201382.","journal-title":"Expert Opin Pharmacother"},{"key":"1037_CR25","doi-asserted-by":"crossref","unstructured":"Verdonschot RG, Dilles T, Cahir C, De Graef M, Holis RV, Fryden J, et al. To Include or Not to Include? A prescription from the pharmacy on how to use active learning assisted screening in systematic reviews. medRxiv. 2025:2025.09.26.25336705.","DOI":"10.1101\/2025.09.26.25336705"},{"issue":"1","key":"1037_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12885-017-3286-5","volume":"17","author":"A Sekulic","year":"2017","unstructured":"Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332.","journal-title":"BMC Cancer"},{"issue":"6","key":"1037_CR27","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/bjd.18552","volume":"182","author":"R Dummer","year":"2020","unstructured":"Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369\u201378.","journal-title":"Br J Dermatol"},{"key":"1037_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/ced\/llaf383","volume":"51","author":"F Venturi","year":"2025","unstructured":"Venturi F, Zuccaro B, Perillo G, Cecchi G, Gaeta A, Gandini S, et al. Management of advanced basal cell carcinoma with hedgehog inhibitors: a real-world prospective comparative study. Clin Exp Dermatol. 2025;51:60\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1037_CR29","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1159\/000531280","volume":"239","author":"M Mannino","year":"2023","unstructured":"Mannino M, Piccerillo A, Fabbrocini G, Quaglino P, Argenziano G, Dika E, et al. Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation of hedgehog pathway inhibitor safety and effectiveness. Dermatology. 2023;239(6):868\u201376.","journal-title":"Dermatology"},{"issue":"3","key":"1037_CR30","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.4081\/dr.2025.10196","volume":"17","author":"M Valenti","year":"2025","unstructured":"Valenti M, Di Giulio S, Carugno A, Frascione P, Marzano AV, Mercuri SR, et al. Real-world experience with vismodegib and sonidegib in advanced basal cell carcinoma: a multicenter Italian study. Dermatol Rep. 2025;17(3):10196.","journal-title":"Dermatol Rep"},{"issue":"6","key":"1037_CR31","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15122","volume":"34","author":"M Gurbuz","year":"2021","unstructured":"Gurbuz M, Dogan I, Akkus E, Ermis H, Utkan G, Vatansever S, et al. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: retrospective real-life data. Dermatol Ther. 2021;34(6):e15122.","journal-title":"Dermatol Ther"},{"issue":"8","key":"1037_CR32","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1111\/ajd.14373","volume":"65","author":"K Truong","year":"2024","unstructured":"Truong K, Peera M, Liu R, Wijaya M, Jones-Caballero M, Araujo RR, et al. Real-world data on the efficacy and safety of hedgehog pathway inhibitors in patients with basal cell carcinoma: experience of a tertiary Australian centre. Australas J Dermatol. 2024;65(8):e248\u201354.","journal-title":"Australas J Dermatol"},{"issue":"5","key":"1037_CR33","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1159\/000530813","volume":"239","author":"V Ruiz-Salas","year":"2023","unstructured":"Ruiz-Salas V, Podlipnik S, Sandoval-Clavijo A, Sanmartin-Jimenez O, Bernia-Petit E, Bonfill-Orti M, et al. Real-world experience with vismodegib on advanced and multiple BCCs: data from the RELIVIS study. Dermatology. 2023;239(5):685\u201393.","journal-title":"Dermatology"},{"issue":"2","key":"1037_CR34","doi-asserted-by":"publisher","first-page":"e2023211","DOI":"10.5826\/dpc.1302a211","volume":"13","author":"N Bendsoe","year":"2023","unstructured":"Bendsoe N, Paoli J, Soderkvist K, Persson B, Halldin C, Ihrlund L, et al. A non-interventional study on vismodegib for basal cell carcinoma in swedish patients. Dermatol Pract Concept. 2023;13(2):e2023211.","journal-title":"Dermatol Pract Concept."},{"issue":"5","key":"1037_CR35","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s13555-021-00588-8","volume":"11","author":"R Gutzmer","year":"2021","unstructured":"Gutzmer R, Loquai C, Robert C, Dreno B, Guminski A, Lewis K, et al. Key clinical adverse events in patients with advanced basal cell carcinoma treated with sonidegib or vismodegib: a post hoc analysis. Dermatol Ther (Heidelb). 2021;11(5):1839\u201349.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"1037_CR36","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ejca.2017.08.022","volume":"86","author":"N Basset-Seguin","year":"2017","unstructured":"Basset-Seguin N, Hauschild A, Kunstfeld R, Grob J, Dreno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1037_CR37","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1111\/jdv.17332","volume":"35","author":"R Gutzmer","year":"2021","unstructured":"Gutzmer R, Schulze HJ, Hauschild A, Leiter U, Meier F, Haferkamp S, et al. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany\u2014the non-interventional study NIELS. J Eur Acad Dermatol Venereol. 2021;35(8):1678\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1037_CR38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1186\/s12885-024-13101-z","volume":"24","author":"R Gutzmer","year":"2024","unstructured":"Gutzmer R, Leiter U, Mohr P, Kahler KC, Ascierto PA, Scalvenzi M, et al. Interim analysis of the multinational, post-authorization safety study (NISSO) to assess the long-term safety of sonidegib in patients with locally advanced basal cell carcinoma. BMC Cancer. 2024;24(1):1401.","journal-title":"BMC Cancer"},{"issue":"1","key":"1037_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262151","volume":"17","author":"A Sekulic","year":"2022","unstructured":"Sekulic A, Yoo S, Kudchadkar R, Guillen J, Rogers G, Chang ALS, et al. Real-world assessment and treatment of locally advanced basal cell carcinoma: findings from the RegiSONIC disease registry. PLoS ONE. 2022;17(1):e0262151.","journal-title":"PLoS ONE"},{"issue":"10","key":"1037_CR40","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","volume":"21","author":"ME Lacouture","year":"2016","unstructured":"Lacouture ME, Dreno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218\u201329.","journal-title":"Oncologist"},{"issue":"10","key":"1037_CR41","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamadermatol.2015.1937","volume":"151","author":"MS Ally","year":"2015","unstructured":"Ally MS, Tang JY, Lindgren J, Acosta-Raphael M, Rezaee M, Chanana AM, et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. JAMA Dermatol. 2015;151(10):1132\u20134.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1037_CR42","first-page":"1689","volume":"24","author":"M Le Moigne","year":"2016","unstructured":"Le Moigne M, Saint-Jean M, Jirka A, Quereux G, Peuvrel L, Brocard A, et al. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer. 2016;24(4):1689\u201395.","journal-title":"Support Care Cancer"},{"issue":"7","key":"1037_CR43","doi-asserted-by":"publisher","first-page":"e298","DOI":"10.1111\/jdv.14844","volume":"32","author":"JGD Cannon","year":"2018","unstructured":"Cannon JGD, Tran DC, Li S, Chang AS. Levocarnitine for vismodegib-associated muscle spasms: a pilot randomized, double-blind, placebo-controlled, investigator-initiated trial. J Eur Acad Dermatol Venereol. 2018;32(7):e298\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1037_CR44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40257-024-00870-3","volume":"25","author":"AS Farberg","year":"2024","unstructured":"Farberg AS, Portela D, Sharma D, Kheterpal M. Evaluation of the tolerability of hedgehog pathway inhibitors in the treatment of advanced basal cell carcinoma: a narrative review of treatment strategies. Am J Clin Dermatol. 2024;25(5):779\u201394.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1037_CR45","doi-asserted-by":"publisher","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","volume":"106","author":"E Basch","year":"2014","unstructured":"Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, et al. Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1037_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0168-2","volume":"17","author":"BJ Edwards","year":"2017","unstructured":"Edwards BJ, Raisch DW, Saraykar SS, Sun M, Hammel JA, Tran HT, et al. Hepatotoxicity with vismodegib: an MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project. Drugs R D. 2017;17(1):211.","journal-title":"Drugs R D"},{"key":"1037_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ajo.2019.04.013","volume":"207","author":"M Eiger-Moscovich","year":"2019","unstructured":"Eiger-Moscovich M, Reich E, Tauber G, Berliner O, Priel A, Ben Simon G, et al. Efficacy of vismodegib for the treatment of orbital and advanced periocular Basal Cell Carcinoma. Am J Ophthalmol. 2019;207:62\u201370.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"1037_CR48","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","volume":"16","author":"MR Migden","year":"2015","unstructured":"Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716.","journal-title":"Lancet Oncol"},{"key":"1037_CR49","first-page":"1","volume":"18","author":"Y Liu","year":"2025","unstructured":"Liu Y, Li G, Wang C, Chen J, Chen L. Comparative safety analysis of Hedgehog inhibitor preparations: insights from the FAERS database. Expert Opin Drug Saf. 2025;18:1\u20138.","journal-title":"Expert Opin Drug Saf"},{"key":"1037_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1497708","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang B, Zhao K, Xian N, Ren L, Liu J, Tu C, et al. Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database. Front Pharmacol. 2025;16:1497708.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1037_CR51","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","volume":"152","author":"SV Mohan","year":"2016","unstructured":"Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma. JAMA Dermatol. 2016;152(5):527\u201332.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"1037_CR52","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","volume":"77","author":"T Bhutani","year":"2017","unstructured":"Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017;77(4):713\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1037_CR53","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jdin.2022.08.027","volume":"10","author":"M Migden","year":"2023","unstructured":"Migden M, Loquai C, Robert C, Baurain JF, Squittieri N, Arntz R, et al. Sonidegib improved quality of life in patients with advanced basal cell carcinoma: results from the phase 2 Basal cell carcinoma outcomes with LDE225 treatment trial through 73 weeks. JAAD Int. 2023;10:31\u20133.","journal-title":"JAAD Int"},{"issue":"6","key":"1037_CR54","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1684\/ejd.2018.3448","volume":"28","author":"J Hansson","year":"2018","unstructured":"Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dreno B, et al. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. Eur J Dermatol. 2018;28(6):775\u201383.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"1037_CR55","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s13555-019-0303-4","volume":"9","author":"A Villani","year":"2019","unstructured":"Villani A, Fabbrocini G, Cappello M, Costa C, Scalvenzi M. Real-life effectiveness of vismodegib in patients with metastatic and advanced basal cell carcinoma: characterization of adverse events and assessment of health-related quality of life using the Dermatology Life Quality Index (DLQI) Test. Dermatol Ther. 2019;9(3):505\u201310.","journal-title":"Dermatol Ther"},{"issue":"8","key":"1037_CR56","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s13555-023-00945-9","volume":"13","author":"G Konidaris","year":"2023","unstructured":"Konidaris G, Rofail D, Randall J, LaFontaine PR, Chen CI, Bury D, et al. Qualitative patient interviews to characterize the human burden of advanced basal cell carcinoma following hedgehog pathway inhibitor treatment. Dermatol Ther. 2023;13(8):1747\u201361.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1037_CR57","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S1470-2045(17)30072-4","volume":"18","author":"B Dreno","year":"2017","unstructured":"Dreno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404\u201312.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1037_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00619-4","volume":"11","author":"K Lewis","year":"2021","unstructured":"Lewis K, Dummer R, Farberg AS, Guminski A, Squittieri N, Migden M. Effects of sonidegib following dose reduction and treatment interruption in patients with advanced basal cell carcinoma during 42-month BOLT trial. Dermatol Ther. 2021;11(6):2225.","journal-title":"Dermatol Ther"},{"key":"1037_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.563404","volume":"10","author":"MC Tronconi","year":"2020","unstructured":"Tronconi MC, Solferino A, Giordano L, Borroni R, Mancini L, Santoro A. Tailored toxicity-driven administration of vismodegib in patients with multiple or locally advanced basal cell carcinoma: a pilot analysis. Front Oncol. 2020;10:563404.","journal-title":"Front Oncol"},{"issue":"4","key":"1037_CR60","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jid.2020.07.036","volume":"141","author":"P Chanu","year":"2021","unstructured":"Chanu P, Musib L, Wang X, Cheeti S, Girish S, Bruno R, et al. Vismodegib efficacy in advanced basal cell carcinoma maintained with 8-week dose interruptions: a model-based evaluation. J Investig Dermatol. 2021;141(4):930\u20133.","journal-title":"J Investig Dermatol"},{"issue":"8","key":"1037_CR61","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/ced\/llaf171","volume":"50","author":"A Villani","year":"2025","unstructured":"Villani A, Genco L, Fornaro L, Potestio L. How the use of sonidegib beyond clinical complete response impacts tolerability in locally advanced basal cell carcinoma: a retrospective monocentric analysis. Clin Exp Dermatol. 2025;50(8):1665\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"16_suppl","key":"1037_CR62","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.1200\/JCO.2025.43.16_suppl.9540","volume":"43","author":"C Resteghini","year":"2025","unstructured":"Resteghini C, Farinatti S, Alberti A, Tovazzi V, Queirolo P, Saponara M, et al. A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (laBCC): the SONIBEC trial. J Clin Oncol. 2025;43(16_suppl):9540.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1037_CR63","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s13555-020-00371-1","volume":"10","author":"M Scalvenzi","year":"2020","unstructured":"Scalvenzi M, Cappello M, Costa C, Fabbrocini G, Luciano M, Villani A. Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity. Dermatol Ther. 2020;10(3):465\u20138.","journal-title":"Dermatol Ther"},{"issue":"5","key":"1037_CR64","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1093\/oncolo\/oyad319","volume":"29","author":"S Alfieri","year":"2024","unstructured":"Alfieri S, Romano R, Marceglia S, De Giorgi V, Peris K, Sollena P, et al. Hedgehog inhibitors beyond clinical complete response in basal cell carcinoma: should i stop or should i go? Oncologist. 2024;29(5):e699\u2013707.","journal-title":"Oncologist"},{"issue":"2","key":"1037_CR65","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/12034754211051234","volume":"26","author":"J Tong","year":"2022","unstructured":"Tong J, Mitchell B, Roth K, Logan D, Ernst S. Real-world experience of vismodegib in advanced basal cell carcinoma at a Canadian cancer center. J Cutan Med Surg. 2022;26(2):143\u20138.","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"1037_CR66","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","volume":"17","author":"JY Tang","year":"2016","unstructured":"Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720\u201331.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1037_CR67","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bjd.20700","volume":"186","author":"BJA Verkouteren","year":"2022","unstructured":"Verkouteren BJA, Cosgun B, Reinders M, Kessler P, Vermeulen RJ, Klaassens M, et al. A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome). Br J Dermatol. 2022;186(2):215\u201326.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1037_CR68","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1136\/jclinpath-2020-206448","volume":"73","author":"Q Sun","year":"2020","unstructured":"Sun Q, Atzmony L, Zaki T, Peng A, Sugarman J, Choate KA. Clues to primary vismodegib resistance lie in histology and genetics. J Clin Pathol. 2020;73(10):678\u201380.","journal-title":"J Clin Pathol"},{"issue":"7","key":"1037_CR69","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","volume":"138","author":"M Ben Ishai","year":"2020","unstructured":"Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I. Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial. JAMA Ophthalmol. 2020;138(7):749\u201355.","journal-title":"JAMA Ophthalmol."},{"issue":"4","key":"1037_CR70","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/IOP.0000000000001251","volume":"35","author":"O Sagiv","year":"2019","unstructured":"Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, et al. Impact of Food and Drug Administration approval of vismodegib on prevalence of orbital exenteration as a necessary surgical treatment for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(4):350\u20133.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"6","key":"1037_CR71","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.abd.2021.04.012","volume":"96","author":"C Xavier","year":"2021","unstructured":"Xavier C, Lopes E, Bexiga C, Moura C, Gouveia E, Duarte AF. Vismodegib for treatment of periocular basal cell carcinoma - 6-year experience from a tertiary cancer center. An Bras Dermatol. 2021;96(6):712\u20136.","journal-title":"An Bras Dermatol"},{"issue":"9","key":"1037_CR72","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s13555-023-00985-1","volume":"13","author":"A Villani","year":"2023","unstructured":"Villani A, Fabbrocini G, Micali G, Fornaro L, Potestio L, Scalvenzi M. The efficacy of sonidegib in treating locally advanced Basal cell carcinoma involving the periocular area. Dermatol Ther (Heidelb). 2023;13(9):2121\u20136.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1037_CR73","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/IOP.0000000000001166","volume":"35","author":"AR Gonzalez","year":"2019","unstructured":"Gonzalez AR, Etchichury D, Gil ME, Del Aguila R. Neoadjuvant vismodegib and Mohs micrographic surgery for locally advanced periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg. 2019;35(1):56\u201361.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"1037_CR74","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ajo.2015.04.040","volume":"160","author":"OK Ozgur","year":"2015","unstructured":"Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, et al. Hedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndrome. Am J Ophthalmol. 2015;160(2):220-7 e2.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"1037_CR75","doi-asserted-by":"publisher","first-page":"e1240","DOI":"10.1002\/onco.13820","volume":"26","author":"A Kahana","year":"2021","unstructured":"Kahana A, Unsworth SP, Andrews CA, Chan MP, Bresler SC, Bichakjian CK, et al. Vismodegib for preservation of visual function in patients with advanced periocular Basal Cell Carcinoma: the VISORB Trial. Oncologist. 2021;26(7):e1240\u20139.","journal-title":"Oncologist"},{"issue":"7","key":"1037_CR76","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1158\/1078-0432.CCR-21-3764","volume":"28","author":"AA Yurchenko","year":"2022","unstructured":"Yurchenko AA, Pop OT, Ighilahriz M, Padioleau I, Rajabi F, Sharpe HJ, et al. Frequency and genomic aspects of intrinsic resistance to vismodegib in locally advanced Basal Cell Carcinoma. Clin Cancer Res. 2022;28(7):1422\u201332.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1037_CR77","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ccell.2015.02.002","volume":"27","author":"SX Atwood","year":"2015","unstructured":"Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):342\u201353.","journal-title":"Cancer Cell"},{"issue":"5","key":"1037_CR78","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.jaad.2014.08.001","volume":"71","author":"T Brinkhuizen","year":"2014","unstructured":"Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, et al. Acquired resistance to the Hedgehog pathway inhibitor Vismodegib due to Smoothened mutations in treatment of locally advanced Basal Cell Carcinoma. J Am Acad Dermatol. 2014;71(5):1005\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1037_CR79","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","volume":"27","author":"HJ Sharpe","year":"2015","unstructured":"Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327\u201341.","journal-title":"Cancer Cell"},{"issue":"4","key":"1037_CR80","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/ng.3525","volume":"48","author":"X Bonilla","year":"2016","unstructured":"Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin Basal Cell Carcinoma. Nat Genet. 2016;48(4):398\u2013406.","journal-title":"Nat Genet"},{"key":"1037_CR81","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000651","author":"IV Litvinov","year":"2021","unstructured":"Litvinov IV, Xie P, Gunn S, Sasseville D, Lefrancois P. The transcriptional landscape analysis of basal cell carcinomas reveals novel signalling pathways and actionable targets. Life Sci Alliance. 2021. https:\/\/doi.org\/10.26508\/lsa.202000651.","journal-title":"Life Sci Alliance"},{"issue":"7","key":"1037_CR82","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jid.2018.11.035","volume":"139","author":"F Kuonen","year":"2019","unstructured":"Kuonen F, Huskey NE, Shankar G, Jaju P, Whitson RJ, Rieger KE, et al. Loss of primary cilia drives switching from Hedgehog to Ras\/MAPK pathway in resistant Basal Cell Carcinoma. J Investig Dermatol. 2019;139(7):1439\u201348.","journal-title":"J Investig Dermatol"},{"issue":"7727","key":"1037_CR83","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-018-0603-3","volume":"562","author":"A Sanchez-Danes","year":"2018","unstructured":"Sanchez-Danes A, Larsimont JC, Liagre M, Munoz-Couselo E, Lapouge G, Brisebarre A, et al. A slow-cycling LGR5 tumour population mediates Basal Cell Carcinoma relapse after therapy. Nature. 2018;562(7727):434\u20138.","journal-title":"Nature"},{"issue":"7727","key":"1037_CR84","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-018-0596-y","volume":"562","author":"B Biehs","year":"2018","unstructured":"Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, et al. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature. 2018;562(7727):429\u201333.","journal-title":"Nature"},{"issue":"5","key":"1037_CR85","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jaad.2019.12.026","volume":"85","author":"BJA Verkouteren","year":"2021","unstructured":"Verkouteren BJA, Wakkee M, van Geel M, van Doorn R, Winnepenninckx VJ, Korpershoek E, et al. Molecular testing in metastatic basal cell carcinoma. J Am Acad Dermatol. 2021;85(5):1135\u201342.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1037_CR86","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","volume":"22","author":"AJ Stratigos","year":"2021","unstructured":"Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, et al. Cemiplimab in locally advanced basal cell carcinoma after Hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848\u201357.","journal-title":"Lancet Oncol"},{"key":"1037_CR87","unstructured":"European Medicines A. CHMP post-authorisation summary of positive opinion for libtayo (cemiplimab): European Medicines Agency; 2023."},{"key":"1037_CR88","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejca.2022.09.013","volume":"177","author":"M Veron","year":"2022","unstructured":"Veron M, Chevret S, Grob JJ, Beylot-Barry M, Saiag P, Flechon A, et al. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to Sonic Hedgehog inhibitors: UNICANCER AcSe NIVOLUMAB trial. Eur J Cancer. 2022;177:103\u201311.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1037_CR89","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jaad.2018.08.017","volume":"80","author":"ALS Chang","year":"2019","unstructured":"Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, et al. Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019;80(2):564\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"1037_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004839","author":"GK In","year":"2022","unstructured":"In GK, Nallagangula A, Choi JS, Tachiki L, Blackburn MJ, Capone S, et al. Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004839.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"1037_CR91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008591","volume":"12","author":"K Fletcher","year":"2024","unstructured":"Fletcher K, Johnson DB. Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update. J Immunother Cancer. 2024;12(7):e008591.","journal-title":"J Immunother Cancer"},{"issue":"225","key":"1037_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115590","volume":"25","author":"VK DeTemple","year":"2025","unstructured":"DeTemple VK, Kaatz M, Stockfleth E, Scheel C, Angela Y, Gutzmer R, et al. Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma. Eur J Cancer. 2025;25(225):115590.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1037_CR93","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2018.1701","volume":"4","author":"AM Goodman","year":"2018","unstructured":"Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncol. 2018;4(9):1237\u201344.","journal-title":"JAMA Oncol"},{"issue":"17","key":"1037_CR94","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1158\/1078-0432.CCR-23-0219","volume":"29","author":"C Pich-Bavastro","year":"2023","unstructured":"Pich-Bavastro C, Yerly L, Di Domizio J, Tissot-Renaud S, Gilliet M, Kuonen F. Activin A-mediated polarization of cancer-associated fibroblasts and macrophages confers resistance to checkpoint immunotherapy in skin Cancer. Clin Cancer Res. 2023;29(17):3498\u2013513.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1037_CR95","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2501269122","volume":"122","author":"Y Che","year":"2025","unstructured":"Che Y, Lee J, Abou-Taleb F, Rieger KE, Satpathy AT, Chang ALS, et al. Induced B cell receptor diversity predicts PD-1 blockade immunotherapy response. Proc Natl Acad Sci USA. 2025;122(18):e2501269122.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"1037_CR96","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.3390\/cancers14215469","volume":"14","author":"VK DeTemple","year":"2022","unstructured":"DeTemple VK, Hassel JC, Sachse MM, Grimmelmann I, Leiter U, Gebhardt C, et al. Reinduction of hedgehog inhibitors after checkpoint inhibition in advanced basal cell carcinoma: a series of 12 patients. Cancers (Basel). 2022;14(21):5469.","journal-title":"Cancers (Basel)."},{"issue":"34","key":"1037_CR97","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1200\/JCO.18.00794","volume":"37","author":"F Herms","year":"2019","unstructured":"Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma after vismodegib discontinuation: a multicenter french study of 116 patients. J Clin Oncol. 2019;37(34):3275\u201382.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1037_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100284","volume":"6","author":"A Bassompierre","year":"2021","unstructured":"Bassompierre A, Dalac S, Dreno B, Neidhardt EM, Maubec E, Capelle C, et al. Efficacy of sonic Hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. ESMO Open. 2021;6(6):100284.","journal-title":"ESMO Open"},{"key":"1037_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100844","volume":"35","author":"N Bertrand","year":"2021","unstructured":"Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma. EClinicalMedicine. 2021;35:100844.","journal-title":"EClinicalMedicine."},{"issue":"1","key":"1037_CR100","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/bjd.17623","volume":"181","author":"SL Soon","year":"2019","unstructured":"Soon SL, Ibrahim SF, Arron ST. A randomized phase II study evaluating Vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned. Br J Dermatol. 2019;181(1):208\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1037_CR101","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jaad.2016.02.1235","volume":"75","author":"GP Kwon","year":"2016","unstructured":"Kwon GP, Ally MS, Bailey-Healy I, Oro AE, Kim J, Chang AL, et al. Update to an open-label clinical trial of Vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016;75(1):213\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1037_CR102","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2014.05.020","volume":"71","author":"MS Ally","year":"2014","unstructured":"Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904-11 e1.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1037_CR103","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00066-015-0902-7","volume":"192","author":"B Schulze","year":"2016","unstructured":"Schulze B, Meissner M, Ghanaati S, Burck I, Rodel C, Balermpas P. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck: first clinical experience with Vismodegib for locally advanced disease. Strahlenther Onkol. 2016;192(1):25\u201331.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"1037_CR104","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/ijd.15836","volume":"61","author":"AD Patel","year":"2022","unstructured":"Patel AD, Ravichandran S, Kheterpal M. Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma. Int J Dermatol. 2022;61(1):118\u201324.","journal-title":"Int J Dermatol"},{"issue":"9","key":"1037_CR105","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1093\/ced\/llae068","volume":"49","author":"M Boileau","year":"2024","unstructured":"Boileau M, Dubois M, Pruvot C, Desmedt E, Templier C, Meyer N, et al. Sequential combination of sonic Hedgehog inhibitors followed by consolidation radiotherapy in locally advanced basal cell carcinoma. Clin Exp Dermatol. 2024;49(9):1024\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"1037_CR106","doi-asserted-by":"publisher","first-page":"e2247","DOI":"10.1002\/onco.13959","volume":"26","author":"JP Weissman","year":"2021","unstructured":"Weissman JP, Samlowski W, Meoz R. Hedgehog inhibitor induction with addition of concurrent superficial radiotherapy in patients with locally advanced basal cell carcinoma: a case series. Oncologist. 2021;26(12):e2247\u201353.","journal-title":"Oncologist"},{"issue":"19","key":"1037_CR107","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.23.01708","volume":"42","author":"CA Barker","year":"2024","unstructured":"Barker CA, Dufault S, Arron ST, Ho AL, Algazi AP, Dunn LA, et al. Phase II, single-arm trial of induction and concurrent vismodegib with curative-intent radiation therapy for locally advanced, unresectable basal cell carcinoma. J Clin Oncol. 2024;42(19):2327\u201335.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1037_CR108","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-024-00798-1","volume":"9","author":"SP Patel","year":"2025","unstructured":"Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, et al. Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. NPJ Precis Oncol. 2025;9(1):24.","journal-title":"NPJ Precis Oncol."},{"issue":"1","key":"1037_CR109","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0277-5379(90)90262-R","volume":"26","author":"P Pfeiffer","year":"1990","unstructured":"Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer. 1990;26(1):73\u20137.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1037_CR110","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12967-017-1225-5","volume":"15","author":"LG Campana","year":"2017","unstructured":"Campana LG, Marconato R, Valpione S, Galuppo S, Alaibac M, Rossi CR, et al. Basal cell carcinoma: 10-year experience with electrochemotherapy. J Transl Med. 2017;15(1):122.","journal-title":"J Transl Med"},{"issue":"1","key":"1037_CR111","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/ijd.17346","volume":"64","author":"A Vass","year":"2025","unstructured":"Vass A, Polgar N, Sandor SA, Agoston D, Rozsa P, Csanyi I, et al. The role of electrochemotherapy in the treatment of locally advanced or recurrent eyelid-periocular basal cell carcinoma: long-term results. Int J Dermatol. 2025;64(1):111\u20138.","journal-title":"Int J Dermatol"},{"issue":"8","key":"1037_CR112","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.3390\/curroncol29080423","volume":"29","author":"G Bertino","year":"2022","unstructured":"Bertino G, Muir T, Odili J, Groselj A, Marconato R, Curatolo P, et al. Treatment of Basal Cell Carcinoma with electrochemotherapy: insights from the InspECT registry (2008\u20132019). Curr Oncol. 2022;29(8):5324\u201337.","journal-title":"Curr Oncol"},{"issue":"12","key":"1037_CR113","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1016\/j.ejso.2016.06.399","volume":"42","author":"LG Campana","year":"2016","unstructured":"Campana LG, Testori A, Curatolo P, Quaglino P, Mocellin S, Framarini M, et al. Treatment efficacy with electrochemotherapy: a multi-institutional prospective observational study on 376 patients with superficial tumors. Eur J Surg Oncol. 2016;42(12):1914\u201323.","journal-title":"Eur J Surg Oncol"},{"issue":"21","key":"1037_CR114","doi-asserted-by":"publisher","first-page":"e97071","DOI":"10.1172\/jci.insight.97071","volume":"2","author":"AN Mirza","year":"2017","unstructured":"Mirza AN, Fry MA, Urman NM, Atwood SX, Roffey J, Ott GR, et al. Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight. 2017;2(21):e97071.","journal-title":"JCI Insight."},{"issue":"17","key":"1037_CR115","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1158\/0008-5472.CAN-14-0317","volume":"74","author":"B Li","year":"2014","unstructured":"Li B, Fei DL, Flaveny CA, Dahmane N, Baubet V, Wang Z, et al. Pyrvinium attenuates Hedgehog signaling downstream of smoothened. Cancer Res. 2014;74(17):4811\u201321.","journal-title":"Cancer Res"},{"issue":"16","key":"1037_CR116","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.3390\/cancers13164227","volume":"13","author":"E Peer","year":"2021","unstructured":"Peer E, Aichberger SK, Vilotic F, Gruber W, Parigger T, Grund-Groschke S, et al. Casein kinase 1D encodes a novel drug target in Hedgehog-GLI-driven cancers and tumor-initiating cells resistant to SMO inhibition. Cancers (Basel). 2021;13(16):4227.","journal-title":"Cancers (Basel)."},{"issue":"7438","key":"1037_CR117","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nature11889","volume":"494","author":"SX Atwood","year":"2013","unstructured":"Atwood SX, Li M, Lee A, Tang JY, Oro AE. GLI activation by atypical protein kinase C iota\/lambda regulates the growth of basal cell carcinomas. Nature. 2013;494(7438):484\u20138.","journal-title":"Nature"},{"issue":"5","key":"1037_CR118","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/ijc.31117","volume":"142","author":"W Gruber","year":"2018","unstructured":"Gruber W, Peer E, Elmer DP, Sternberg C, Tesanovic S, Del Burgo P, et al. Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance. Int J Cancer. 2018;142(5):968\u201375.","journal-title":"Int J Cancer"},{"issue":"3","key":"1037_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.43","volume":"2","author":"J Zhao","year":"2014","unstructured":"Zhao J, Quan H, Xie C, Lou L. NL-103, a novel dual-targeted inhibitor of histone deacetylases and Hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations. Pharmacol Res Perspect. 2014;2(3):e00043.","journal-title":"Pharmacol Res Perspect"},{"key":"1037_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102848","volume":"131","author":"JC Janssen","year":"2024","unstructured":"Janssen JC, van Dijk B, Hoeijmakers LL, Grunhagen DJ, Bramer WM, Verhoef C, et al. Local administration of immunotherapy for patients with skin cancer: a systematic review. Cancer Treat Rev. 2024;131:102848.","journal-title":"Cancer Treat Rev"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01037-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01037-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01037-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:02:59Z","timestamp":1784188979000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01037-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1037"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01037-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Klara Mosterd received consulting or speaker fees from Pierre Fabre, Janssen-Cilag, and Almirall, and a research grant from Sun Pharma, outside the submitted work. Anna A. L. Massella Patsea and Babette J. A. Verkouteren declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent for Publication, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The literature extraction file underlying this article will be shared on reasonable request to the corresponding author.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the study conception and design. Anna Massella Patsea developed the search strategy. Anna Massella Patsea and Babette Verkouteren independently performed screening and data extraction. Anna Massella Patsea wrote the first draft of the manuscript. Babette Verkouteren and Klara Mosterd contributed to study selection, data interpretation, critical revision of the manuscript, and supervision. All authors read and approved the final manuscript.","order":4,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}